Canada markets closed

IMV Inc. (IMV.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
1.7600-0.1600 (-8.33%)
At close: 03:59PM EST
Full screen
Previous Close1.9200
Open1.9000
Bid1.7500 x 0
Ask1.8700 x 0
Day's Range1.7500 - 1.9100
52 Week Range1.6800 - 5.8600
Volume83,717
Avg. Volume84,938
Market Cap144.571M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • Business Wire

    Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress

    DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 02, 2021--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and blood cancers, today announced new translational data implicating B cells in the clinical benefit induced by MVP-S treatment in ovarian cancer patients. These data will be showcased at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) congress, December 8-

  • Business Wire

    IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

    DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., November 30, 2021--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and blood cancers while preserving patients’ quality of life, today announced that the first patient with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer has been dosed with its lead compound, maveropepimut-S (MVP-S, formerly known as DPX-Survivac). In this tri

  • Business Wire

    IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference

    DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., November 23, 2021--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that IMV’s executive management team will be participating in the upcoming Piper Sandler Virtual Healthcare Conference.